Getting to Know the New JAKs on the Block: Pharmacy-Focused Insights for Atopic Dermatitis and Alopecia Areata - September 28, 2021 ALSHP Webinar
CME ONLY: Thank you for attending Getting to Know the New JAKs on the Block: Pharmacy-Focused Insights for Atopic Dermatitis and Alopecia Areata on September 28, 2021. Once logged in, please click on "Take Course" on the right-hand side and your enrollment will be recorded. You will be prompted to claim your credit on the following page.
- Go to the University of Rhode Island College of Pharmacy Continuing Professional Development Learning Management System located at www.uripharmacycpd.org and create an account using your email address and pharmacy license number.* Enter all of the required account information. Verify that your date of birth and NABP ID Number are entered correctly. Click the “Update Account” button at the bottom of the page to save the account information.
- Complete the program evaluations. Evaluations must be completed within 60 days of the program.
- Log onto www.uripharmacycpd.org
- Select Complete Live Activity Post-Test/Evaluations and select the program date and title of the activity (see below).
- Enter the program evaluation code (BUJAK64) and complete program evaluation.
- Select submit at the bottom of the page.
- You will receive a confirmation message of evaluation completion and notification that your ce data was reported to the CPE Monitor.
The evaluation access codes for this program are: “Getting to Know the New JAKs on the Block: Pharmacy-Focused Insights for Atopic Dermatitis and Alopecia Areata” BUJAK64
This curriculum is intended for a broad audience of community pharmacists, dermatologic specialty pharmacists, and managed care professionals involved in the care and treatment of patients with AD and/or AA.
At the conclusion of this activity, participants will be able to:
1. Explore the changing paradigm of AA and AD disease presentation and treatment approach.
2. Assess and interpret the latest clinical trial data among emerging oral agents in AA and/or AD and terms of therapeutic target, safety, efficacy, and tolerability.
3. Recognize the potential place in therapy and monitoring aspects for the emerging agents in AD and AA in order to effectively engage patients in shared decision-making for their treatment plan.
4. Outline a plan to proactively identify and remove barriers for health maintenance services and medication access in underserved patients with AA and/or AD.
This activity is funded by an independent medical education grant from Pfizer.
Steering Committee Disclosures
Peter Lio, MD is on the advisory board for Johnson and Johnson, DermTap, Inc., Intraderm Pharmaceuticals, Regeneron, Sanofi US Services, Realm Therapeutics, Menlo Therapeutics, Syncere Skin Systems, DermVeda, gpower, inc. UCB, Altus Labs, Dermavant Sciences, Micreos Human Health B.V., Arbonne, YobeeCare, Inc., Bodwell, ASLAN Pharmaceuticals, Almirall, MaskSense, Castle Biosciences, and Verrica Pharmaceuticals Inc. He is a stockholder for Modernizing Medicine, LearnHealth/LearnSkin, and Medable. He is a speaker for Pierre Fabre Dermatologie, Regeneron, La Roche-Posay Laboratorie Pharmaceutique, Galderma USA, Eli Lilly and Company, and Pfizer Inc. Dr. Lio is a consultant for Exeltis, Theraplex, Odeza LLC, L'Oreal USA Inc., Franklin BioScience, AbbVie, Kiniksa Pharmaceuticals, Ltd, Eli Lilly and Company, Unilever, and Dermira, Amyris, Inc., LEO Laboratories, Ltd, Burt’s Bees, Kimberly Clark, Sonica, LLC, and Concerto Biosciences. Dr. Lio receives research support from AOBiome, LLC, Regeneron, and AbbVie. Dr. Lio receives royalties from Theraplex.
Amanuel Kehasse, PharmD, PhD (Course Director); Dana McCormick, RPh, FAMCP; and Lynne Goldberg, MD have no relevant financial relationships to disclose
Natalie Sanfratello, MPH, Planning Committee; Mike Burk, Planning Committee, Mary-Jane Kanaczet, M. Ed., Director, Office of Continuing Professional Development, College of Pharmacy, University of Rhode Island,, and Jessica Martin, PhD, Medical Editor have no relevant relationships to disclose.
Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Boston University School of Medicine designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The University of Rhode Island College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This is an application-based educational activity. Pharmacists will receive 1.0 contact hours (0.10 ceus) for the educational activity. No partial credit is available. ACPE Universal Activity Number (UAN): 0060-9999-21-023-L01-P
- 1.00 AMA PRA Category 1 Credit™
Boston University Chobanian & Avedisian School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Boston University Chobanian & Avedisian School of Medicine designates this Enduring activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 ParticipationBoston University Chobanian & Avedisian School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Please click on "Take Course" above to begin the credit claiming process.
THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.